EUCOPE gives voice to small to medium-sized innovative companies active in the field of pharmaceuticals, biotechnologies, and medical technologies at the European level. Learn more about the benefits of membership with EUCOPE.
It is the organisation that represents companies like PTC – relentlessly innovative, typically smaller in size and focused on developing therapies for people with rare diseases. There are many important legislative and policy discussions going on which will shape the healthcare sector in general and the biopharmaceutical industry, in particular for, years to come. EUCOPE ensures very effectively that the voices, opinions and expertise of PTC and others are heard.
Through our membership of EUCOPE, we’ve been able to far more effectively understand, follow and contribute to areas important to our patients, our business and our industry sector.
Over the years, we have come to appreciate the quality of your support – both from a strategic and day-to-day, tactical perspective – as well as the tailored attention that your leadership and staff continuously pay to any of your members, large or small, especially as you accomplish your mission of guiding us through often complex EU legislative processes and political decisions and of raising the attractiveness of Europe for our industry.
EUCOPE provides expert intelligence to its members, enabling us to stay on top of the latest policy issues, as well as valuable networking opportunities. EUCOPE is a strong voice for industry to when communicating the value that companies bring to health systems across Europe and globally.
EUCOPE provides a platform for discussions on major healthcare topics and developments. Your ad hoc expertise on national market access issues, as well your close relationship with many national medicines and HTA agencies in Europe, are particularly useful for us, and I’m sure for many of the other members.
We believe that EUCOPE’s mission to facilitate trusted relationships with established stakeholders at the EU and national levels and giving greater voice to companies regardless of their size is very important to enabling innovation and the creation of synergies for the benefit of patients.
What is unique about EUCOPE is that it provides the perfect mix of EU affairs and country perspectives. We appreciate EUCOPE’s willingness to explore new areas of engagement if it is important to its member companies as well as the swift and agile way it operates.
We see EUCOPE as an important advocate on policy issues for our industry in Brussels and a critical voice that represents small, medium, and global companies. Having EUCOPE champion the cutting-edge research and inherent risk-taking innovation required by our industry with policymakers helps to promote well-balanced policy proposals that allow all aspects of our industry to flourish.
As a specialized biotherapeutics company, we specifically value EUCOPE’s network and trusted relationships with established stakeholders at the EU and national levels to connect and share experiences with the European Commission, the European Parliament, Member States’ representatives, patient organizations, healthcare professionals and payers, academics, and other industry associations.
EUCOPE’s successful intervention on behalf of its members and the broader life sciences industry with stakeholders spanning policymakers, payers, and influencers is unparalleled. MAP has proudly supported EUCOPE throughout our 10 years including many joint webinars and representation in payer meetings such as NICE, and we look forward to many more.
MAP Patient Access
One distinct feature of EUCOPE is its country and market access focus and expertise. Another one is its bottom-up approach and willingness to be innovation-driven before consensus-driven and allowing any of its members regardless of its size to bring forward an idea or project.
Two significant advantages of working with EUCOPE are their deep understanding of country reimbursement pathways for advanced pharmaceutical and medical technologies – enabling sharing of learnings across orphan medicines, gene therapies and advanced diagnostics; secondly, their operating model and relationships with national biotech and diagnostic organisations enables flexible engagement with national, as well as EU decision-makers.
EUCOPE really helps us to keep an eye on European developments and to give a voice to companies that are mid-sized (for now) and follow their passion to serve patients more than shareholder-driven profits.
Sitting together with many sector-mates, listening to their experiences, sharing best practices, and being part of a lobby association aimed at making pharma innovation advance meaningfully for the best of the patients, is what made Ferrer want to be part of EUCOPE.
Stay in touch
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View